Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.616 USD | +6.21% | +6.98% | -94.41% |
May. 24 | Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial | CI |
May. 06 | Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 190K |
---|---|---|---|---|---|
Net income 2024 * | -16M | Net income 2025 * | -28M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.24
x | P/E ratio 2025 * |
-0.39
x | Employees | 6 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
Latest transcript on Allarity Therapeutics, Inc.
1 day | +6.21% | ||
1 week | +6.98% | ||
1 month | -51.50% | ||
3 months | -92.03% | ||
6 months | -94.43% | ||
Current year | -94.41% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Jensen
FOU | Founder | 46 | 20-05-31 |
Joan Brown
DFI | Director of Finance/CFO | 71 | 21-09-20 |
Chief Tech/Sci/R&D Officer | 63 | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 56 | 22-09-30 | |
Thomas Jensen
FOU | Founder | 46 | 20-05-31 |
Joseph Vazzano
BRD | Director/Board Member | 40 | 23-07-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.616 | +6.21% | 9,002,213 |
24-05-30 | 0.58 | -1.76% | 2,312,547 |
24-05-29 | 0.5904 | +2.64% | 2,898,348 |
24-05-28 | 0.5752 | -0.10% | 1,741,440 |
24-05-24 | 0.5758 | -3.99% | 1,858,352 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-94.41% | 190K | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- ALLR Stock